Tradestie Institutional Equity Comparison Engine

GLUE vs VTYX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VTYX Overall Edge

VTYX Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ventyx Biosciences, Inc. Common Stock (VTYX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GLUE counters with relative strength in Valuation. Fundamentally, GLUE trades at 10.0x Forward P/E with -214.5% operating margin (+325.8% YoY revenue) versus VTYX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, GLUE sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against VTYX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GLUE
GLUE 10.0x vs VTYX N/M Fwd P/E
Growth & Margin Winner VTYX
Op Margin -214.5% vs 0.0% ยท YoY +325.8% vs +0.0%
Momentum & Technical Winner VTYX
1Y -35.9% vs +786.1% ยท 52W Pos 1% vs 55%
Options & Structure Winner VTYX
BREAKDOWN (16th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.18
-2.03% 1D
Market Cap $795.5M
1M Return -5.75%
1Y Return -35.89%
Forward P/E 10.0x
Unified AI Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
VTYX NASDAQ
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
1M Return +0.36%
1Y Return +786.08%
Forward P/E N/M
Unified AI Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GLUE -35.89% VTYX +786.08% Spread: +21.18 pp (VTYX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
GLUE TTM Op. Margin: -214.5% VTYX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GLUE vs VTYX. Trailing 12-month operating profitability (GLUE -214.5% vs VTYX 0.0%) and valuation multiples (GLUE 10.0x vs VTYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GLUE (4) vs VTYX (6)
Institutional Metric GLUE VTYX Criterion Row Winner
Market Capitalization Scale $795.5M $1.0B Larger Scale VTYX
Trailing P/E Ratio Valuation 10.0x N/M Lower Multiple GLUE
Forward P/E Ratio Valuation 10.0x N/M Lower Multiple GLUE
Revenue Growth (YoY) Growth +325.8% +0.0% Higher Growth GLUE
Operating Margin (TTM) Profitability -214.5% 0.0% Higher Margin VTYX
Net Profit Margin Profitability -186.2% 0.0% Higher Margin VTYX
Return on Equity (ROE) Capital Efficiency -35.3% -45.4% Higher ROE GLUE
52-Week Range Position Momentum 1% ($9โ€“$26) 55% ($1โ€“$25) Stronger Trend VTYX
Beta / 30D Volatility Risk Regime 0.95ฮฒ ยท 53% Vol 2.07ฮฒ ยท 2% Vol Lower Realized Risk VTYX
Unified Institutional Score Composite Signal 44.2 / 100 (HOLD) 50.4 / 100 (HOLD) Higher Composite VTYX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GLUE vs VTYX Buy Guide
GLUE BREAKDOWN
85d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live GLUE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VTYX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live VTYX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GLUE nor VTYX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.